SU6656
Product Sizes
50 mg
£ POA
HY-B0789-50MG
10 mg
£ POA
HY-B0789-10MG
25 mg
£ POA
HY-B0789-25MG
5 mg
£ POA
HY-B0789-5MG
100 mg
£ POA
HY-B0789-100MG
10mM/1mL
£ POA
HY-B0789-10MM
About this Product
- SKU:
- HY-B0789
- CAS Number:
- 330161-87-0
- Extra Details:
- SU6656 is a Src family kinases inhibitor with IC50s of 280; 20; 130; 170 nM for Src; Yes; Lyn; and Fyn; respectively. SU6656 inhibits FAK phosphorylation at Y576/577; Y925; Y861 sites. SU6656 also inhibits p-AKT.
- Molecular Weight:
- 371.45
- Purity:
- 99.01
- References:
- [1]Blake RA, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000 Dec;20(23):9018-27.|[2]Veracini L, et al. Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas. Oncotarget. 2014 Dec 26.|[3]Wu ML, et al. Divergent signaling pathways cooperatively regulate TGFβ induction of cysteine-rich protein 2 in vascular smooth muscle cells. Cell Commun Signal. 2014 Mar 28;12:22.|[4]Ondrusová L, et al. Inhibition of mTORC1 by SU6656, the selective Src kinase inhibitor, is not accompanied by activation of Akt/PKB signalling in melanoma cells. Folia Biol (Praha). 2013;59(4):162-7.|[5]Kumar A, et al. Pharmacological investigations on possible role of Src kinases in neuroprotective mechanism of ischemic postconditioning in mice. Int J Neurosci. 2014 Oct;124(10):777-86.|[6]Liu XF, et al. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors. Mol Cancer Ther. 2014 Jan;13(1):82-9.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- PI3K/Akt/mTOR;Protein Tyrosine Kinase/RTK
